Efficacy 、Safety and PK of SHR-1314 in Patients With Moderate-to-Severe Plaque Psoriasis

Moderate-to-Severe Plaque Psoriasis Clinical Trial

Official title:
A Randomized, Double-blind, Multicenter, Placebo-controlled, Phase III Adaptive Study of SHR-1314 to Assess Efficacy and Safety in Patients With Moderate-to-Severe Plaque Psoriasis

Status Not yet recruiting

Clinical Trial Summary

The purpose of this study is to assess efficacy, safety, pharmacokinetics and immunogenicity of subcutaneous SHR-1314 in Patients with Moderate-to-Severe Plaque Psoriasis

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Moderate-to-Severe Plaque Psoriasis
Psoriasis

Clinical Trial Details

NCT number	NCT04839016
Study type	Interventional
Source	Jiangsu HengRui Medicine Co., Ltd.
Contact	Yang Shen
Phone	0518-82342973
Email	Shenyang@hrglobe.cn
Status	Not yet recruiting
Phase	Phase 3
Start date	April 25, 2021
Completion date	August 30, 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05787236` - A Study of Moderate-to-severe Plaque Psoriasis Patients Response to Secukinumab Treatment in Real-world Setting
Active, not recruiting	`NCT04612699` - A Phase 2 Study of Jaktinib in Participants With Moderate to Severe Psoriasis	Phase 2
Not yet recruiting	`NCT06258668` - Real-World Safety and Effectiveness of Sotyktu (Deucravacitinib) in Patients With Moderate-to-Severe Plaque Psoriasis in Korea
Recruiting	`NCT06142357` - Secukinumab Drug Survival, Effectiveness and Tolerability in Pediatric Patients With Psoriasis
Completed	`NCT06182384` - A Clinical Study to Compare the Safety and Pharmacokinetics of SHR-1314 Injection in Healthy Subjects at Different Specifications Devices	Phase 1
Recruiting	`NCT03710681` - A Safety Study of Multiple Subcutaneous (s.c.) Injections of SHR-1314 in Adults With Moderate-to-severe Plaque Psoriasis	Phase 1